Sept 1 (Reuters) - The U.S. Federal Trade Commission has allowed Amgen Inc to move ahead with its $27.8 billion deal to buy Horizon Therapeutics, CNBC reported on Friday. (Reporting by Manas Mishra in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
305.8 USD | +1.59% | -0.01% | +6.17% |
28/05 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
28/05 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.17% | 16TCr | |
+40.73% | 74TCr | |
+32.83% | 60TCr | |
-6.30% | 35TCr | |
+15.15% | 32TCr | |
+4.05% | 28TCr | |
+15.00% | 24TCr | |
+9.78% | 21TCr | |
-5.52% | 21TCr | |
-0.45% | 16TCr |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- U.S. FTC allows Amgen to move forward with $27.8 bln Horizon deal - CNBC